Actions of Vibrio vulnificus Metalloprotease on Human Plasma Proteinase‐Proteinase Inhibitor Systems: A Comparative Study of Native Protease with Its Derivative Modified by Polyethylene Glycol

Vibrio vulnificus, an opportunistic human pathogen causing wound infection and septicemia, produces a metalloprotease (VVP) which is suspected to be a virulent determinant. The interactions of VVP, as well as its derivative (PEG1‐VVP) modified with polyethylene glycol, with a variety of human plasma proteins were investigated. We found that native VVP and its derivative were able to act directly on many biologically important human plasma proteins even in the presence of α‐macroglobulin, the sole plasma inhibitor of native VVP. The activities of both classical and alternative pathways of the complement cascade system were drastically abolished by incubation with either VVP. Furthermore, these proteases rapidly digested the Aα‐chain of human fibrinogen into fragment(s) with no clotting ability. Therefore both VVPs are thought to function as a fibrinogenolytic enzyme, causing delay of the coagulation reaction. VVP and PEG1‐VVP were also shown to destroy plasma proteinase inhibitors including α1‐proteinase inhibitor, a major inhibitor in human plasma. Because endogenous proteolytic enzymes and their inhibitors are indispensable in maintaining physiological homeostasis, these findings suggest that VVP (and PEG1‐VVP) may cause an imbalance of human plasma proteinase‐proteinase inhibitor systems, thus eliciting an immunocompromised state in the host and facilitating the development of a systemic V. vulnificus infection such as septicemia.

[1]  R. Miller,et al.  Complete primary structure and biochemical properties of gilatoxin, a serine protease with kallikrein-like and angiotensin-degrading activities. , 1993, The Journal of biological chemistry.

[2]  S. Miyoshi,et al.  Chemical modification of Vibrio vulnificus metalloprotease with activated polyethylene glycol. , 1993, FEMS microbiology letters.

[3]  J. Oliver,et al.  Regulation of proteolytic activity of Vibrio vulnificus by iron-containing compounds. , 1993, Microbial pathogenesis.

[4]  S. Miyoshi,et al.  Activation mechanism of human Hageman factor‐plasma kallikreinkinin system by Vibrio vulnificus metalloprotease , 1992, FEBS letters.

[5]  S. Miyoshi,et al.  Significant role of an exocellular protease in utilization of heme by Vibrio vulnificus , 1992, Infection and immunity.

[6]  S. Miyoshi,et al.  Alpha-macroglobulin-like plasma inactivator for Vibrio vulnificus metalloprotease. , 1991, Journal of biochemistry.

[7]  N. Nishino,et al.  Pseudomonas aeruginosa alkaline proteinase might share a biological function with plasmin. , 1991, Biochimica et biophysica acta.

[8]  H. Shon,et al.  Vibrio vulnificus septicemia in Korea: clinical and epidemiologic findings in seventy patients. , 1991, Journal of the American Academy of Dermatology.

[9]  C. Hack,et al.  Quantification of Functional and Inactivated α2-Macroglobulin in Sepsis , 1991, Thrombosis and Haemostasis.

[10]  S. Miyoshi,et al.  Inhibitory effect of α2-macroglobulin on Vibrio vulnificus protease , 1989 .

[11]  L. Sottrup-jensen Alpha-macroglobulins: structure, shape, and mechanism of proteinase complex formation. , 1989, The Journal of biological chemistry.

[12]  H. Maeda,et al.  Activation of hageman factor and prekallikrein and generation of kinin by various microbial proteinases. , 1989, The Journal of biological chemistry.

[13]  H. Maeda,et al.  Inactivation of various proteinase inhibitors and the complement system in human plasma by the 56-kilodalton proteinase from Serratia marcescens , 1989, Infection and immunity.

[14]  S. Moestrup,et al.  Characterization, size estimation and solubilization of alpha-macroglobulin complex receptors in liver membranes. , 1989, Biochimica et biophysica acta.

[15]  S. Miyoshi,et al.  Role of the Protease in the Permeability Enhancement by Vibrio vulnificus , 1988, Microbiology and immunology.

[16]  R. Howard,et al.  Soft-tissue infections caused by halophilic marine vibrios. , 1988, Archives of surgery.

[17]  H. Maeda,et al.  Internalization of serratial protease into cells as an enzyme-inhibitor complex with alpha 2-macroglobulin and regeneration of protease activity and cytotoxicity. , 1987, The Journal of biological chemistry.

[18]  F. Martínez-Brotons,et al.  Plasma Kallikrein-Kinin System in Patients with Uncomplicated Sepsis and Septic Shock-Comparison with Cardiogenic Shock , 1987, Thrombosis and Haemostasis.

[19]  S. Miyoshi,et al.  Activation of the plasma kallikrein-kinin system by Vibrio vulnificus protease , 1987, Infection and immunity.

[20]  M. Silverberg,et al.  The coagulation-kinin pathway of human plasma , 1987 .

[21]  S. Shinoda,et al.  Inhibitory Effect of Capsular Antigen of Vibrio vulnificus on Bactericidal Activity of Human Serum , 1987, Microbiology and immunology.

[22]  S. Miyoshi,et al.  Purification and Characterization of Vibrio vulnificus Protease , 1987, Microbiology and immunology.

[23]  S. Miyoshi,et al.  Histamine release from rat mast cells by Vibrio vulnificus protease , 1986 .

[24]  M. Kothary,et al.  Production and partial characterization of an elastolytic protease of Vibrio vulnificus , 1985, Infection and immunity.

[25]  P. Taylor Bactericidal and bacteriolytic activity of serum against gram-negative bacteria. , 1983, Microbiological reviews.

[26]  J. Travis,et al.  Inactivation of human plasma alpha 1-proteinase inhibitor by a metalloproteinase from Serratia marcescens. , 1982, Biochimica et biophysica acta.

[27]  W. Schleuning,et al.  Isolation and characterization of urokinase from human plasma. , 1982, The Journal of biological chemistry.

[28]  M. Hoylaerts,et al.  Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator. , 1982, The Journal of biological chemistry.

[29]  S. Pizzo,et al.  Clearance and binding of two electrophoretic "fast" forms of human alpha 2-macroglobulin. , 1981, The Journal of biological chemistry.

[30]  S. Iwanaga,et al.  New fluorogenic peptide substrates for plasmin. , 1980, Journal of biochemistry.

[31]  S. Iwanaga,et al.  A new fluorogenic substrate method for the estimation of kallikrein in urine. , 1980, Journal of biochemistry.

[32]  J. Howard,et al.  Structural characterization of human alpha2-macroglobulin subunits. , 1979, The Journal of biological chemistry.

[33]  H. Tsuzuki,et al.  Protease and elastase of Pseudomonas aeruginosa: inactivation of human plasma alpha 1-proteinase inhibitor , 1979, Infection and immunity.

[34]  P. Blake,et al.  Disease caused by a marine Vibrio. Clinical characteristics and epidemiology. , 1979, The New England journal of medicine.

[35]  Tetsuo Takahashi,et al.  Synthesis of a Key Fluorogenic Amide, L-Arginine-4-methylcoumaryl-7-amide (L-Arg-MCA) and Its Derivatives. Fluorescence Assays for Trypsin and Papain , 1977 .

[36]  S. Iwanaga,et al.  New Fluorogenic Substrates for α-Thrombin, Factor Xa, Kallikreins, and Urokinase , 1977 .

[37]  K. Miller,et al.  Elastase of Pseudomonas aeruginosa: Inactivation of Complement Components and Complement-Derived Chemotactic and Phagocytic Factors , 1974, Infection and immunity.

[38]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[39]  R. Colman,et al.  Interaction of plasma kallikrein with the C1 inhibitor. , 1970, Journal of immunology.

[40]  E. Cliffton,et al.  The determination of plasma fibrinogen by turbidity with ammonium sulfate. , 1953, Archives of biochemistry and biophysics.

[41]  H. Maeda,et al.  Different binding kinetics of Serratia 56K protease with plasma alpha 2-macroglobulin and chicken egg white ovomacroglobulin. , 1987, Journal of biochemistry.

[42]  S. Miyoshi,et al.  Enhancement of vascular permeability due to histamine-releasing effect of Vibrio vulnificus protease in rat skin , 1987 .

[43]  M. Silverberg,et al.  The coagulation-kinin pathway of human plasma. , 1987, Blood.

[44]  G. Salvesen,et al.  Human plasma proteinase inhibitors. , 1983, Annual review of biochemistry.

[45]  A. Barrett [54] α2-Macroglobulin , 1981 .

[46]  J. Travis,et al.  [55] Human α1-proteinase inhibitor , 1981 .